Unknown

Dataset Information

0

EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.


ABSTRACT: Epigenetic alterations are major drivers of follicular lymphomagenesis, and these alterations are frequently caused by mutations in or upregulation of EZH2, a histone methyltransferase responsible for PRC2-mediated gene repression. EZH2 hyperactivation increases proliferation of B cells and prevents them from exiting the germinal center, favoring lymphomagenesis. The first FDA-approved EZH2 inhibitor is tazemetostat, which is orally available and targets both mutant and wild-type forms of the protein to induce cell cycle arrest and apoptosis of lymphoma cells in preclinical models. Phase II trials have shown objective response rates of 69% for patients with lymphoma-carrying EZH2 mutations and 35% for those with wild-type EZH2 without major toxicity, leading to tazemetostat approval for this cancer by the US FDA in June 2020.

SUBMITTER: Julia E 

PROVIDER: S-EPMC9892962 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.

Julia Edith E   Salles Gilles G  

Future oncology (London, England) 20210312 17


Epigenetic alterations are major drivers of follicular lymphomagenesis, and these alterations are frequently caused by mutations in or upregulation of <i>EZH2</i>, a histone methyltransferase responsible for PRC2-mediated gene repression. EZH2 hyperactivation increases proliferation of B cells and prevents them from exiting the germinal center, favoring lymphomagenesis. The first FDA-approved EZH2 inhibitor is tazemetostat, which is orally available and targets both mutant and wild-type forms of  ...[more]

Similar Datasets

| S-EPMC8165870 | biostudies-literature
| S-EPMC8893153 | biostudies-literature
| S-EPMC8427481 | biostudies-literature
| S-EPMC8409398 | biostudies-literature
| S-EPMC7935786 | biostudies-literature
| S-EPMC8864656 | biostudies-literature
| S-EPMC11785659 | biostudies-literature
| S-EPMC10028236 | biostudies-literature
| S-EPMC5176374 | biostudies-literature
| S-EPMC7869188 | biostudies-literature